Transdel Enrolls First Patient For Ketotransdel(TM) Phase 3 Clinical Trial Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing non-invasive, topically administered medications, announced it has enrolled its first patient in the Phase 3 registration trial for Ketotransdel(TM).
Source: www.medicalnewstoday.comRecruitment Completed In Ofatumumab NHL Front Line Study Genmab A/S (OMX: GEN) announced it has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma (NHL) patients in the Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). "We are happy to finish enrolment in this first study with ofatumumab in front line follicular NHL patients," said Lisa N. Drakeman, Ph.D., Chief Executive Officer at Genmab.
Source: www.medicalnewstoday.comEmisphere Announces Recruitment Phase III Study For Oral Osteoarthritis Treatment Emisphere Technologies, Inc. (Nasdaq: EMIS) announced that Novartis Pharma AG and Nordic Bioscience have completed recruitment for a multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere's proprietary Eligen Technology to treat patients with osteoarthritis of the knee.
Source: www.medicalnewstoday.comBaxter Initiates Phase III Trial For The Treatment Of Alzheimer's Disease Baxter
Healthcare Corporation announced initiation of a Phase III clinical trial following U.S. Food and Drug Administration (FDA) review of its investigational new drug application to evaluate GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)], marketed as KIOVIG in European Union, for the treatment of mild-to-moderate Alzheimer's disease.
Source: www.medicalnewstoday.comHelix Receives Approval To Open Sites In Germany For Its Ongoing Clinical Trial With Topical Interferon Alpha-2b In Patients With Ano-Genital Warts Helix BioPharma announced that it has received the necessary regulatory approvals to open clinical sites in Germany to expand upon its clinical trial with Topical Interferon Alpha-2b in patients with ano-genital warts, which is presently underway in Sweden. "We are pleased to have received approval to open these additional clinical sites," said John Docherty, President of Helix BioPharma.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 AM
